Infertility, FemaleACONCT04482751
The Relationship Between Serum AMH Dynamics and Early or Normal Ovarian Response to Corifollitropin Alfa
An observational study of Infertility, Female, run by Azienda Ospedaliero-Universitaria di Modena at 1 site in Italy.
Trial summary
The objective of this study is to evaluate the trend of serum AMH during IVF (in vitro fertilization) cycles, in particular the possible relationship between the dynamics of AMH and the early or normal response to therapies for controlled ovarian stimulation with corifollitropin alfa. Read more about this study
- Who is it for?
- Ages 18 to 46 years, women only
- Conditions the study is for
- Infertility, Female
- What is being tested?
- Corifollitropin alfa
- How many people
- 80 participants
- Where
- 1 siteItaly
- Study dates
- 1 Aug 2020to 30 Sep 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 46 years
- Women only
- No healthy volunteers
- Adult
Study population: Infertile patients
Who may be able to join
- basal serum FSH concentration below 20 UI/L
- age between 18 and 46 years
- body weight > 60 kg
- use of corifollitrofin alpha for ovarian stimulation.
Who cannot join
- contraindications to IVF
- irregular menstrual cycles
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
Policlinico di Modena
Modena, Modena - MO, 41123
Antonio La Marca, 3384795303, antlamarca@libero.it
About this study
Official title: An Observational Single Center Study to Identify the Relationship Between Serum AMH Dynamics and Early or Normal Ovarian Response to Corifollitropin Alfa (ACO Study)
The objective of this study is to evaluate the trend of serum AMH during IVF (in vitro fertilization) cycles, in particular the possible relationship between the dynamics of AMH and the early or normal response to therapies for controlled ovarian stimulation with corifollitropin alfa. The secondary objective is to study the association between the number of follicles equal to or greater than 17 mm on the eighth day of ovarian stimulation and the decline in AMH, and to assess the predictability of the need to add additional therapies after the first week of stimulation ovarian.
Read the detailed description
The study is observational and it is monocentric, and it will involve 80 patients. Patients' data, extrapolated from the medical records of the Department of Reproductive Medicine in the Policlinico Hospital in Modena, will be collected in an internal database for analysis. The inclusion criteria for the population included in the study will be: 1) basal serum FSH concentration below 20 UI/L; 2) age between 18 and 46 years; 3) body weight > 60 kg; 4) use of corifollitrofin alpha for ovarian stimulation. The following parameters will be evaluated: the age of the patients, their weight, their body mass index (BMI), duration of infertility, cycle characteristics; basal (day 2) AMH, AFC measurement, basal estradiol, basal progesterone, basal FSH, basal LH, and those same values on day 5 and day 8 of ovarian stimulation; follicles ≥ 17 mm on day 8, type of gonadothropin further added, days of stimulation with the further gonadothropin and its units per day, AMH on trigger day and the number of oocytes retrieved. The confidentiality of the informations will be guaranteed by anonymized data analysis. All the data are commonly recorded in our clinical practice.
The observed period will be of 12 months. The date of conclusion of the study, after favorable opinion of the Ethics Committee and the authorization of the Company Management, is scheduled for June 2021.
To guarantee the consent and the information of the patients involved in the study, the Information Sheet and the relative Consent Form are attached. We consider appropriate to inform the General Physician of the enlisted patients about the study: the Information Letter for the General Physician is therefore attached.
Variables/Time Points of Interest
The variables which will be recorded on cycle day 2 of a spontaneous menstruation (stimulation day 1 with Corifollitropin alfa) are: woman's age (years), weight (kg), body-mass-index (kg/m2), duration of infertility (months), cycle length (in days, by patient recall), cycle regularity (yes/no; deviation of > 5 days from two consecutive cycles is considered an irregular cycle), total number of antral follicles (2-10 mm) in both ovaries (AFC) measured by a transvaginal scan and serum AMH (ng/ml), oestradiol, progesterone, FSH and LH.
Patients will return every two days to the clinic for a transvaginal ultrasound from stimulation day 5 up to and including the day of hCG. Serum hormone concentrations (FSH, LH, oestradiol, progesterone and AMH) will be measured on stimulation days 5 and 8 and on the day of hCG.
All hormones reported above will be measured in the central lab of the ospital as per routine practice. Remaining serum will be used for the AMH assay. The measurement of the AMH will ber profrmed in the ObGyn University research Lab.
- Conditions
- Infertility, Female
- Being tested
- Corifollitropin alfa
- Medical subject headings
- Infertility, Female
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Corifollitropin alfaDrug
Also called no other interventions
AMH will be measured during ovarian stimulation with corifollitropin alfa
| Study group | Role | What they receive |
|---|---|---|
| Infertile women | the group consists of 80 infertile patients undergoing IVF Receives: Drug: Corifollitropin alfa |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in serum Antimullerian Hormone (AMH) levels during ovarian stimulation
Serum concentrations of AMH will be measured during ovarian stimulation with corifollitropin alfa.
Measured: AMH will be measured at day 2, day 5, day 8 and the last day (usually day 11) of ovarian stimulation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jul 2020
- Study start1 Aug 2020
- Primary completion30 Jun 2023 (estimated)
- Study completion30 Sep 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Infertility, FemaleStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Azienda Ospedaliero-Universitaria di Modena
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Antonio La Marca, Azienda Ospedaliero-Universitaria di Modena
- Investigators
- Antonio La Marca, Principal investigator, University of Modena and Reggio Emilia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04482751
- Sponsor's protocol ID
- 184/2020
- Acronym
- ACO
- Status last verified
- Feb 2023
- First submitted
- 3 Jul 2020
- Last updated
- 8 Feb 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 8 Feb 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Observational Single Center Study to Identify the Relationship Between Serum AMH Dynamics and Early or Normal Ovarian Response to Corifollitropin Alfa (ACO Study)
- ClinicalTrials.gov ID
- NCT04482751
- Acronym / sponsor ID
- ACO / 184/2020
- Conditions
- Infertility, Female
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Azienda Ospedaliero-Universitaria di ModenaUniversity, hospital or other
- Study start
- 1 Aug 2020 (actual)
- Primary completion
- 30 Jun 2023 (estimated)
- Study completion
- 30 Sep 2023 (estimated)
- First posted
- 23 Jul 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to evaluate the trend of serum AMH during IVF (in vitro fertilization) cycles, in particular the possible relationship between the dynamics of AMH and the early or normal response to therapies for controlled ovarian stimulation with corifollitropin alfa. The secondary objective is to study the association between the number of follicles equal to or greater than 17 mm on the eighth day of ovarian stimulation and the decline in AMH, and to assess the predictability of the need to add additional therapies after the first week of stimulation ovarian.
Detailed description
The study is observational and it is monocentric, and it will involve 80 patients. Patients' data, extrapolated from the medical records of the Department of Reproductive Medicine in the Policlinico Hospital in Modena, will be collected in an internal database for analysis. The inclusion criteria for the population included in the study will be: 1) basal serum FSH concentration below 20 UI/L; 2) age between 18 and 46 years; 3) body weight > 60 kg; 4) use of corifollitrofin alpha for ovarian stimulation. The following parameters will be evaluated: the age of the patients, their weight, their body mass index (BMI), duration of infertility, cycle characteristics; basal (day 2) AMH, AFC measurement, basal estradiol, basal progesterone, basal FSH, basal LH, and those same values on day 5 and day 8 of ovarian stimulation; follicles ≥ 17 mm on day 8, type of gonadothropin further added, days of stimulation with the further gonadothropin and its units per day, AMH on trigger day and the number of oocytes retrieved. The confidentiality of the informations will be guaranteed by anonymized data analysis. All the data are commonly recorded in our clinical practice.
The observed period will be of 12 months. The date of conclusion of the study, after favorable opinion of the Ethics Committee and the authorization of the Company Management, is scheduled for June 2021.
To guarantee the consent and the information of the patients involved in the study, the Information Sheet and the relative Consent Form are attached. We consider appropriate to inform the General Physician of the enlisted patients about the study: the Information Letter for the General Physician is therefore attached.
Variables/Time Points of Interest
The variables which will be recorded on cycle day 2 of a spontaneous menstruation (stimulation day 1 with Corifollitropin alfa) are: woman's age (years), weight (kg), body-mass-index (kg/m2), duration of infertility (months), cycle length (in days, by patient recall), cycle regularity (yes/no; deviation of > 5 days from two consecutive cycles is considered an irregular cycle), total number of antral follicles (2-10 mm) in both ovaries (AFC) measured by a transvaginal scan and serum AMH (ng/ml), oestradiol, progesterone, FSH and LH.
Patients will return every two days to the clinic for a transvaginal ultrasound from stimulation day 5 up to and including the day of hCG. Serum hormone concentrations (FSH, LH, oestradiol, progesterone and AMH) will be measured on stimulation days 5 and 8 and on the day of hCG.
All hormones reported above will be measured in the central lab of the ospital as per routine practice. Remaining serum will be used for the AMH assay. The measurement of the AMH will ber profrmed in the ObGyn University research Lab.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Infertile women | – | Drug: Corifollitropin alfathe group consists of 80 infertile patients undergoing IVF |
Who may qualify
- Ages
- 18 to 46 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Infertile patients
Key inclusion criteria (4 listed)
- basal serum FSH concentration below 20 UI/L
- age between 18 and 46 years
- body weight > 60 kg
- use of corifollitrofin alpha for ovarian stimulation.
Key exclusion criteria (2 listed)
- contraindications to IVF
- irregular menstrual cycles
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Corifollitropin alfaAlso: no other interventionsAMH will be measured during ovarian stimulation with corifollitropin alfa | Drug | Infertile women |
Primary outcome
Changes in serum Antimullerian Hormone (AMH) levels during ovarian stimulation
Time frame: AMH will be measured at day 2, day 5, day 8 and the last day (usually day 11) of ovarian stimulation
Serum concentrations of AMH will be measured during ovarian stimulation with corifollitropin alfa.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Feb 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Infertility, Female
RecruitingObservational study
Safety and Efficacy of Corifollitropin Alfa N02 Injection in Elderly Women Undergoing Assisted Reproductive Technology (ART)
Infertility
RecruitingObservational study
Inherited Reproductive Disorders
Genetic Disorder, Infertility
RecruitingObservational study
Biorepository in Participants Who Undergo OTC for Gonadotoxic Therapy
Acute Ovarian Failure, Infertility
Not yet recruitingObservational study
Linzagolix in Adenomyosis and Recurrent Implantation Failure
Adenomyosis of Uterus, Implantation Failure
Recruiting
225 IU Versus 300 IU Starting FSH Dose in PPOS for Good-Prognosis Women
Infertility (IVF Patients), Infertility Assisted Reproductive Technology
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Antonio La Marca principal investigator
University of Modena and Reggio Emilia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Infertility, Female, run by Azienda Ospedaliero-Universitaria di Modena at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 8 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Antonio La Marca (+390594224671, antlamarca@libero.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in serum Antimullerian Hormone (AMH) levels during ovarian stimulation (time frame: AMH will be measured at day 2, day 5, day 8 and the last day (usually day 11) of ovarian stimulation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Feb 2023.